MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597776 | Name: RB 101

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RB 101 inhibits enkephalinase and aminopeptidases; biologically cleaved at disulfide to produce inhibitors of both aminopeptidase N and neutral endopeptidase.

Chemical Structure

RB 101
RB 101
CAS#135949-60-9

Theoretical Analysis

MedKoo Cat#: 597776

Name: RB 101

CAS#: 135949-60-9

Chemical Formula: C31H38N2O3S3

Exact Mass: 582.2045

Molecular Weight: 582.83

Elemental Analysis: C, 63.88; H, 6.57; N, 4.81; O, 8.24; S, 16.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
135949-60-9
Synonym
RB 101; RB-101; RB101;
IUPAC/Chemical Name
benzyl (3-((2-amino-4-(methylthio)butyl)disulfanyl)-2-benzylpropanoyl)-L-phenylalaninate
InChi Key
QXXMSEVVNUSHKJ-PPUMFKDSSA-N
InChi Code
InChI=1S/C31H38N2O3S3/c1-37-18-17-28(32)23-39-38-22-27(19-24-11-5-2-6-12-24)30(34)33-29(20-25-13-7-3-8-14-25)31(35)36-21-26-15-9-4-10-16-26/h2-16,27-29H,17-23,32H2,1H3,(H,33,34)/t27?,28?,29-/m0/s1
SMILES Code
O=C(OCC1=CC=CC=C1)[C@H](CC2=CC=CC=C2)NC(C(CSSCC(N)CCSC)CC3=CC=CC=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 582.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jayaram A, Singh P, Noreuil T, Fournié-Zaluski MC, Carp HM. RB 101, a purported pro drug inhibitor of enkephalin metabolism, is antinociceptive in pregnant mice. Anesth Analg. 1997 Feb;84(2):355-8. PubMed PMID: 9024028. 2: Coudoré-Civiale MA, Méen M, Fournié-Zaluski MC, Boucher M, Roques BP, Eschalier A. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats. Br J Pharmacol. 2001 May;133(1):179-85. PubMed PMID: 11325808; PubMed Central PMCID: PMC1572770. 3: Ruiz F, Fournié-Zaluski MC, Roques BP, Maldonado R. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. Br J Pharmacol. 1996 Sep;119(1):174-82. PubMed PMID: 8872371; PubMed Central PMCID: PMC1915744. 4: Baamonde A, Daugé V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournié-Zaluski MC, Roques BP. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol. 1992 Jun 5;216(2):157-66. PubMed PMID: 1327810. 5: Maldonado R, Valverde O, Ducos B, Blommaert AG, Fournie-Zaluski MC, Roques BP. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308. Br J Pharmacol. 1995 Mar;114(5):1031-9. PubMed PMID: 7780637; PubMed Central PMCID: PMC1510310. 6: Ortega-Alvaro A, Chover-Gonzalez AJ, Lai-Kuen R, Mico JA, Gibert-Rahola J, Fournié-Zaluski MC, Roques BP, Maldonado R. Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord. Eur J Pharmacol. 1998 Sep 4;356(2-3):139-48. PubMed PMID: 9774243. 7: Ruiz-Gayo M, Baamonde A, Turcaud S, Fournie-Zaluski MC, Roques BP. In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding. Brain Res. 1992 Feb 7;571(2):306-12. PubMed PMID: 1319268. 8: Kolosova LI, Moiseeva AB, Riabchikova OV, Akoev GN. [Effect of RB-101, inhibitor of enkephalin degrading enzymes, on recovery of conductivity of the injured sciatic nerve in rats]. Ross Fiziol Zh Im I M Sechenova. 1997 Nov-Dec;83(11-12):74-8. Russian. PubMed PMID: 9541959. 9: Noble F, Coric P, Turcaud S, Fournié-Zaluski MC, Roques BP. Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101. Eur J Pharmacol. 1994 Mar 3;253(3):283-7. PubMed PMID: 8200422. 10: Maldonado R, Derrien M, Noble F, Roques BP. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport. 1993 Jul;4(7):947-50. PubMed PMID: 8369487. 11: Smadja C, Ruiz F, Coric P, Fournié-Zaluski MC, Roques BP, Maldonado R. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology (Berl). 1997 Aug;132(3):227-36. PubMed PMID: 9292622. 12: Dauge V, Corringer PJ, Roques BP. CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101. Pharmacol Biochem Behav. 1995 Feb;50(2):133-9. PubMed PMID: 7740050. 13: Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC, Roques BP. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther. 1992 Apr;261(1):181-90. PubMed PMID: 1560364. 14: Valverde O, Blommaert AG, Fournié-Zaluski MC, Roques BP, Maldonado R. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Eur J Pharmacol. 1995 Nov 3;286(1):79-93. PubMed PMID: 8566154. 15: Smadja C, Maldonado R, Turcaud S, Fournie-Zaluski MC, Roques BP. Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology (Berl). 1995 Aug;120(4):400-8. PubMed PMID: 8539320. 16: Valverde O, Fournié-Zaluski MC, Roques BP, Maldonado R. Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. Eur J Pharmacol. 1996 Sep 19;312(1):15-25. PubMed PMID: 8891574. 17: Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther. 1994 Jul;270(1):77-88. PubMed PMID: 8035345. 18: Lantero A, Tramullas M, Pílar-Cuellar F, Valdizán E, Santillán R, Roques BP, Hurlé MA. TGF-β and opioid receptor signaling crosstalk results in improvement of endogenous and exogenous opioid analgesia under pathological pain conditions. J Neurosci. 2014 Apr 9;34(15):5385-95. doi: 10.1523/JNEUROSCI.4405-13.2014. PubMed PMID: 24719115. 19: Tejedor-Real P, Micó JA, Smadja C, Maldonado R, Roques BP, Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol. 1998 Jul 31;354(1):1-7. PubMed PMID: 9726624. 20: Xu XJ, Elfvin A, Hao JX, Fournié-Zaluski MC, Roques BP, Wiesenfeld-Hallin Z. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides. 1997 Jun;31(3):287-91. PubMed PMID: 9243527.

View History

Razupenem

Razupenem